Trial intelligence / Profile preview

Surufatinib plus PD-1/PD-L1 antibody maintenance in ES-SCLC

CTR20221855Phase 2Completed

Sponsor

HUTCHMED

Start

Jul 2022

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1